Follow the clinical evidence, regulatory status and safety context—then connect the science to vendor documentation and current market data.
Educational research only, not medical advice. Approval status, evidence quality and commercial availability are kept separate.
Fresh from the research desk
bpc-157
Oral BPC-157 is marketed for convenience and gut claims; injectables dominate recovery forums. Both rest on preclinical data — not proven human route equivalence.
Read the full analysisExplore by research lane
Each lane separates approval status, human evidence and research-only claims before you drill into an individual compound.
Weight management
Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.
Open research laneRepair and recovery
Compare healing peptides such as BPC-157 and TB-500 by evidence quality, mechanism, research status and practical limitations.
Open research laneGH axis
Compare growth hormone peptides including ipamorelin, CJC-1295 and tesamorelin by GH-axis mechanism, approval status, half-life and evidence score.
Open research laneBrain and focus
Compare cognitive peptides such as Selank and Semax by mechanism, route, regional clinical history, evidence score and research limitations.
Open research laneSkin, hair and healthspan
Compare longevity peptides by evidence quality, mechanism and practical research limits, starting with GHK-Cu and copper peptide data.
Open research laneEditorial vendor audit
Our vendor reviews separate public batch documents, commercial claims, prices and affiliate relationships instead of compressing them into one vague rating.
Read the market methodologyAscension Peptides
An evidence-led review of public batch records, pricing, shipping, research-use status and what PeptideStat did not independently verify.
Read the Ascension reviewResearch archive
193 total · newest first
glp-1
Orforglipron is the oral small-molecule GLP-1 sold as Foundayo. It is not a peptide, but it matters for peptide readers because it changes the oral GLP-1 comparison.
glp-1
Pemvidutide is an investigational GLP-1/glucagon dual agonist peptide with human MASH and liver-fat data. The strongest claim is MASH resolution signal, not proven fibrosis benefit.
glp-1
The current Ozempic label includes a kidney-outcome indication for adults with type 2 diabetes and chronic kidney disease. FLOW is the main trial to understand, not a general kidney-health claim.
glp-1
Zepbound is FDA approved for moderate-to-severe obstructive sleep apnea in adults with obesity. The evidence is strong for that population, but it is not a replacement for diagnosis or PAP planning.
glp-1
Tirzepatide labels give a specific backup contraception window for oral contraceptives. Semaglutide evidence is different, but vomiting, diarrhea and pregnancy planning still matter.
glp-1
Hair shedding can happen during GLP-1 weight loss, but the best explanation is usually telogen effluvium from rapid weight change, low intake or physiologic stress.
hormone
Fertility peptide claims mix approved IVF drugs with early kisspeptin research and loose hormone marketing. The evidence depends on the exact peptide and protocol.
peptide-safety
Peptide cancer risk depends on the exact peptide, receptor pathway, patient context and evidence source. A GLP-1 label warning is not the same as a tanning-peptide case report or a GH-axis theory.
gut-peptide
Linzess and Trulance are oral GC-C agonist peptide drugs for constipation-related disorders, but their labels, doses, evidence bases and practical tradeoffs differ.
bone
Tymlos and Forteo are anabolic osteoporosis peptide drugs that both activate PTH1 signaling, but their molecules, labels, evidence anchors and safety details differ.
somatostatin
Octreotide, lanreotide and pasireotide are related somatostatin analogs, but their labels, receptor profiles, formulations and safety tradeoffs differ.
somatostatin
PRRT is a regulated nuclear-medicine treatment for somatostatin-receptor-positive neuroendocrine tumors, not a generic peptide wellness protocol.
PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.
Full disclosure →